Advanced therapies for inherited optic neuropathies

Area of Science:

• Ophthalmology
• Genetics
• Neuroscience

Background:

• Inherited optic neuropathies (IONs), including Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (ADOA), result in irreversible vision loss due to retinal ganglion cell degeneration.
• Mitochondrial dysfunction is a key mechanism underlying these conditions, impacting cellular health and leading to progressive vision impairment.

Purpose of the Study:

• To critically appraise current and emerging therapeutic strategies for inherited optic neuropathies.
• To discuss the challenges and future directions for translating these therapies into clinical practice for patients with IONs.

Main Methods:

• Review of recent advancements in understanding the molecular genetic pathways of retinal ganglion cell loss in IONs.
• Appraisal of clinical trial data for existing treatments like idebenone and gene replacement therapy for LHON.
• Evaluation of novel approaches for ADOA, including variant-agnostic gene expression modulation.
• Assessment of cutting-edge strategies such as gene editing and stem cell-based optic nerve regeneration.

Main Results:

• Clinical trials show efficacy for idebenone and gene replacement therapy in LHON.
• Innovative gene expression modulation techniques are being explored for ADOA.
• Gene editing and stem cell therapies represent future regenerative approaches for optic nerve damage.

Conclusions:

• Significant progress in understanding IONs and developing therapeutic strategies offers hope for vision restoration.
• Overcoming barriers to translation, including understanding genetic heterogeneity and optimizing patient selection, is crucial for advancing treatments.
• Future research should focus on personalized medicine to accelerate the development of transformative therapies for inherited optic neuropathies.